Patents by Inventor Alex Godwood

Alex Godwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20230303707
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Application
    Filed: February 14, 2023
    Publication date: September 28, 2023
    Applicant: MEDIMMUNE LIMITED
    Inventors: Rachel Patricia MOATE, Alex GODWOOD, Ethan Paul GRANT, Martin Michael Kari SCHWICKART, Carlos CHAVEZ, Meina LIANG, Tomas Mikael MUSTELIN, Zhengbin YAO, Koustubh RANADE
  • Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
    Patent number: 11613580
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: March 28, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Rachel Patricia Moate, Alex Godwood, Ethan Paul Grant, Martin Michael Kari Schwickart, Carlos Chavez, Meina Liang, Tomas Mikael Mustelin, Zhengbin Yao, Koustubh Ranade
  • ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20200317793
    Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
    Type: Application
    Filed: May 23, 2017
    Publication date: October 8, 2020
    Inventors: Rachel Patricia MOATE, Alex GODWOOD, Ethan Paul GRANT, Martin Michael Kari SCHWICKART, Carlos CHAVEZ, Meina LIANG, Tomas Mikael MUSTELIN, Zhengbin YAO, Koustubh RANADE
  • TREATMENT FOR RHEUMATOID ARTHRITIS
    Publication number: 20170260276
    Abstract: Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 14, 2017
    Inventors: DAVID CLOSE, ALEX GODWOOD, MARK HOPTON
  • Treatment For Rheumatoid Arthritis
    Publication number: 20140335081
    Abstract: Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFR?). Use of GM-CSFR? inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate.
    Type: Application
    Filed: October 10, 2012
    Publication date: November 13, 2014
    Applicant: Medlmmune Limited
    Inventors: Alex Godwood, Fabio Magrini